Rigel Pharmaceuticals Inc
NASDAQ:RIGL

Watchlist Manager
Rigel Pharmaceuticals Inc Logo
Rigel Pharmaceuticals Inc
NASDAQ:RIGL
Watchlist
Price: 41.17 USD -2.09% Market Closed
Market Cap: 747.2m USD
Section:
 

Relative Value

The Relative Value of one RIGL stock under the Base Case scenario is hidden USD. Compared to the current market price of 41.17 USD, Rigel Pharmaceuticals Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RIGL Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

2.6
P/S
P/S
Price to Sales
2.6
vs History
63
vs Industry
78
Median 3Y
2.3
Median 5Y
16.3
Industry
7.9
Forward
2.5
More Details
6.6
P/E
P/E
Price to Earnings
6.6
vs History
17
vs Industry
8
Median 3Y
-10.1
Median 5Y
-35.3
Industry
23.7
Forward
6.2
More Details
11
P/OCF
P/OCF
Price to OCF
11
vs History
28
vs Industry
13
Median 3Y
-18.4
Median 5Y
-18.4
Industry
22
More Details
12.2
P/FCFE
P/FCFE
Price to FCFE
12.2
vs History
23
vs Industry
11
Median 3Y
-12.9
Median 5Y
-22
Industry
23.8
More Details
6.4
P/B
P/B
Price to Book Value
6.4
vs History
44
vs Industry
0
Median 3Y
-7.9
Median 5Y
4.3
Industry
3.3
More Details
2.3
EV/S
EV/S
Enterprise Value to Sales
2.3
vs History
65
vs Industry
69
Median 3Y
2.1
Median 5Y
16.2
Industry
8.3
Forward
2.2
More Details
2.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.4
vs History
65
vs Industry
70
Median 3Y
2.4
Median 5Y
16.6
Industry
10.1
More Details
5.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
5.3
vs History
17
vs Industry
10
Median 3Y
-13.8
Median 5Y
-36.7
Industry
6.4
Forward
5.1
More Details
5.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
5.4
vs History
17
vs Industry
9
Median 3Y
-12.7
Median 5Y
-36.2
Industry
7
Forward
5.1
More Details
9.4
EV/OCF
EV/OCF
Enterprise Value to OCF
9.4
vs History
28
vs Industry
13
Median 3Y
-17.8
Median 5Y
-17.8
Industry
8.3
More Details
9.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
9.4
vs History
19
vs Industry
10
Median 3Y
-12.8
Median 5Y
-27.3
Industry
6.5
More Details
6.3
EV/IC
EV/IC
Enterprise Value to IC
6.3
vs History
65
vs Industry
35
Median 3Y
4.7
Median 5Y
39.1
Industry
5.7
More Details

Multiples Across Competitors

RIGL Competitors Multiples
Rigel Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Rigel Pharmaceuticals Inc
NASDAQ:RIGL
749m USD 2.6 6.6 5.3 5.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 794 036.5 -160 618 -195 041.5 -192 815.9
US
Abbvie Inc
NYSE:ABBV
392.9B USD 6.6 167.5 16.2 23
US
Amgen Inc
NASDAQ:AMGN
170.1B USD 4.7 24.3 17.6 17.6
US
Gilead Sciences Inc
NASDAQ:GILD
150.9B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.5B USD 9.8 31.1 22.8 23.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 084.7 -531.9 -579.2 -563.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.6B USD 5.5 17 16.1 18.3
AU
CSL Ltd
ASX:CSL
89.1B AUD 3.8 19.8 13.3 16.5
NL
argenx SE
XBRU:ARGX
46B EUR 15 35.3 61 62.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
51.8B USD 16.1 1 188.8 156.1 189.3
P/E Multiple
Earnings Growth PEG
US
Rigel Pharmaceuticals Inc
NASDAQ:RIGL
Average P/E: 167.7
6.6
79%
0.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 618 N/A N/A
US
Abbvie Inc
NYSE:ABBV
167.5
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.3
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.1
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
9%
1.9
AU
CSL Ltd
ASX:CSL
19.8
11%
1.8
NL
argenx SE
XBRU:ARGX
35.3
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 188.8
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Rigel Pharmaceuticals Inc
NASDAQ:RIGL
Average EV/EBITDA: 35.7
5.3
91%
0.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 041.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.2
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.6
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.8
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.1
11%
1.5
AU
CSL Ltd
ASX:CSL
13.3
8%
1.7
NL
argenx SE
XBRU:ARGX
61
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
156.1
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Rigel Pharmaceuticals Inc
NASDAQ:RIGL
Average EV/EBIT: 41
5.4
77%
0.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 815.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.6
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.8
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.3
13%
1.4
AU
CSL Ltd
ASX:CSL
16.5
11%
1.5
NL
argenx SE
XBRU:ARGX
62.6
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
189.3
N/A N/A

See Also

Summary
RIGL intrinsic value, competitors valuation, and company profile.
DCF Valuation
RIGL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RIGL stock valuation using valuation multiples.
Wall Street Estimates
RIGL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RIGL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 302,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.